Dr. Scher on Promise of Liquid Biopsies in Prostate Cancer

Howard I. Scher, MD
Published: Tuesday, Feb 07, 2017



Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.

In prostate cancer, the numbers of mutations that clearly predict for sensitivity are fewer, Scher explains. Additionally, it is more difficult to identify the types of changes that are predictive using circulating tumor cell DNA, although there have been many technological advancements.  

Research has shown that liquid biopsies can detect overexpression or amplification of the androgen receptor, which is turning out to be a predictor of nonresponse. Now, the assays have to get to the point of establishing analytical validity, he adds. The whole concept of companion diagnostics is where the field is headed, and it is imperative to monitor the change in a tumor over time. 


 


Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.

In prostate cancer, the numbers of mutations that clearly predict for sensitivity are fewer, Scher explains. Additionally, it is more difficult to identify the types of changes that are predictive using circulating tumor cell DNA, although there have been many technological advancements.  

Research has shown that liquid biopsies can detect overexpression or amplification of the androgen receptor, which is turning out to be a predictor of nonresponse. Now, the assays have to get to the point of establishing analytical validity, he adds. The whole concept of companion diagnostics is where the field is headed, and it is imperative to monitor the change in a tumor over time. 


 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x